BioCryst Pharmaceuticals Announces Termination of Merger Agreement with Idera Pharmaceuticals
BioCryst Pharmaceuticals, Inc. (BCRX)
Last biocryst pharmaceuticals, inc. earnings: 3/5 07:05 am
Check Earnings Report
US:NASDAQ Investor Relations:
biocryst.gcs-web.com/investor-relations
Company Research
Source: Business Wire
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) (“BioCryst”) today announced that it has terminated the previously announced merger agreement with Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) (“Idera”) following the BioCryst stockholders’ failure to approve the adoption of the merger agreement at the BioCryst Special Meeting of Stockholders held today. “We respect and understand the views of our stockholders and are moving forward fully-focused on executing our business plan as a standalone company,” said Jon P. Stonehouse, BioCryst’s President and Chief Executive Officer. “The BioCryst Board and management team remain confident in BCX-7353 and our ability to execute on our plan and advance our programs.” Robert A. Ingram, Chairman of the Board, said, “We are focused on serving the interests of all stockholders in their desire for BioCryst to pursue
Show less
Read more
Impact Snapshot
Event Time:
BCRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BCRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BCRX alerts
High impacting BioCryst Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
BCRX
News
- BioCryst Announces Approval of ORLADEYO® (berotralstat) by the Brazilian Health Regulatory AgencyGlobeNewswire
- Pint Pharma Announces the Approval of ORLADEYO® (berotralstat), the First Oral Therapy Indicated for Preventing Hereditary Angioedema (HAE) Attacks in Adult and Pediatric Patients Aged 12 and Older in Brazil [Yahoo! Finance]Yahoo! Finance
- BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $12.00 price target on the stock.MarketBeat
- BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
- BioCryst to Present at Upcoming Investor ConferencesGlobeNewswire
BCRX
Earnings
- 2/26/24 - Miss
BCRX
Sec Filings
- 4/2/24 - Form 4
- 3/4/24 - Form 4
- 3/4/24 - Form 4
- BCRX's page on the SEC website